PL2252312T3 - Sposoby zapobiegania lub leczenia insulinooporności - Google Patents

Sposoby zapobiegania lub leczenia insulinooporności

Info

Publication number
PL2252312T3
PL2252312T3 PL09707235T PL09707235T PL2252312T3 PL 2252312 T3 PL2252312 T3 PL 2252312T3 PL 09707235 T PL09707235 T PL 09707235T PL 09707235 T PL09707235 T PL 09707235T PL 2252312 T3 PL2252312 T3 PL 2252312T3
Authority
PL
Poland
Prior art keywords
preventing
methods
insulin resistance
treating insulin
treating
Prior art date
Application number
PL09707235T
Other languages
English (en)
Polish (pl)
Inventor
P Darrell Neufer
Ethan J Anderson
Hazel H Szeto
Original Assignee
Univ Cornell
Univ East Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell, Univ East Carolina filed Critical Univ Cornell
Publication of PL2252312T3 publication Critical patent/PL2252312T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL09707235T 2008-02-07 2009-02-06 Sposoby zapobiegania lub leczenia insulinooporności PL2252312T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2688208P 2008-02-07 2008-02-07
EP09707235.9A EP2252312B1 (en) 2008-02-07 2009-02-06 Methods for preventing or treating insulin resistance
PCT/US2009/033440 WO2009100363A2 (en) 2008-02-07 2009-02-06 Methods for preventing or treating insulin resistance

Publications (1)

Publication Number Publication Date
PL2252312T3 true PL2252312T3 (pl) 2014-10-31

Family

ID=40952720

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09707235T PL2252312T3 (pl) 2008-02-07 2009-02-06 Sposoby zapobiegania lub leczenia insulinooporności

Country Status (12)

Country Link
US (7) US8088727B2 (enExample)
EP (7) EP2252312B1 (enExample)
JP (6) JP5453320B2 (enExample)
CN (2) CN104107417B (enExample)
CA (1) CA2713150C (enExample)
CY (1) CY1115305T1 (enExample)
DK (1) DK2252312T3 (enExample)
ES (1) ES2458870T3 (enExample)
PL (1) PL2252312T3 (enExample)
PT (1) PT2252312E (enExample)
SI (1) SI2252312T1 (enExample)
WO (1) WO2009100363A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2604285T1 (sl) 2003-05-01 2014-12-31 Cornell Research Foundation, Inc. Postopek in nosilni kompleksi za dovajanje molekul celicam
KR101426070B1 (ko) 2005-09-16 2014-08-01 코넬 리서치 화운데이션,인크. Ｃｄ36 발현을 감소시키는 방법
ES2458870T3 (es) * 2008-02-07 2014-05-07 Cornell University Procedimientos para prevenir o tratar la resistencia a la insulina
CN102573881A (zh) * 2009-03-20 2012-07-11 通用医疗公司以马萨诸塞州通用医疗公司名义经营 预防和治疗烧伤损伤和继发性并发症的方法
EP3067061A1 (en) * 2009-08-12 2016-09-14 Cornell University Methods for preventing or treating metabolic syndrome
LT3708178T (lt) * 2009-08-24 2023-12-27 Stealth Biotherapeutics Inc. Peptidas, skirtas naudoti makulos degeneracijos prevencijai arba gydymui
CA2776581C (en) * 2009-10-05 2020-12-15 Cornell University Methods for the prevention or treatment of heart failure
US20130190244A1 (en) * 2009-12-31 2013-07-25 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
US20120329730A1 (en) * 2010-01-25 2012-12-27 Institut De Recherches Cliniques De Montreal Aromatic-cationic peptides and uses of same
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
GB201018125D0 (en) * 2010-10-26 2010-12-08 Marealis As Peptide
WO2013086020A1 (en) * 2011-12-09 2013-06-13 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
WO2013126597A1 (en) * 2012-02-22 2013-08-29 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
CN107320712A (zh) 2012-03-30 2017-11-07 康德生物医疗技术公司 用于预防和治疗神经病的方法和组合物
US10188693B2 (en) * 2012-08-02 2019-01-29 Stealth Biotherapeutics Corp Methods for treatment of atherosclerosis
CA2894182A1 (en) * 2012-12-06 2014-06-12 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
MX392555B (es) 2016-09-07 2025-03-24 Univ Temple Composiciones y métodos para el tratamiento de resistencia a la insulina.
SG11202008348SA (en) 2018-03-07 2020-09-29 Univ Temple Compositions and methods for treatment of insulin resistance
AU2019230139A1 (en) * 2018-03-07 2020-09-24 Temple University - Of The Commonwealth System Of Higher Education Compositions and methods for treatment of insulin resistance
TW202206062A (zh) 2020-04-24 2022-02-16 美國坦普大學 高等教育聯邦系統 治療非酒精性脂肪肝炎的方法
JP2023541403A (ja) 2020-09-09 2023-10-02 ソーシャル・プロフィット・ネットワーク ビオチンをミトコンドリアに送達するための方法及び組成物
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
US20240122884A1 (en) * 2022-10-03 2024-04-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of n-lactoyl-phenylalanine and other n-lactoyl-amino acids

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
EP0350221B1 (en) 1988-06-30 1996-04-17 Astra Aktiebolag Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same
US5747641A (en) 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
DE69630918T2 (de) 1995-06-09 2004-10-28 Hisamitsu Pharmaceutical Co., Inc., Tosu Matrix für Iontophorese
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
EP1037911A4 (en) 1997-12-10 2003-07-23 Univ Washington ANTI-PATHOGEN SYSTEM AND METHOD FOR USE THEREOF
US6268398B1 (en) 1998-04-24 2001-07-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
CA2339218C (en) * 1998-07-31 2008-10-28 Mount Sinai Hospital Methods and compositions for increasing insulin sensitivity
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
EP1226115A4 (en) 1999-10-04 2006-03-15 Univ New Jersey Med NEW CARBAMATES AND UREES
US6759520B1 (en) 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
EP1303186B1 (en) 2000-07-18 2011-01-26 Cornell Research Foundation, Inc. Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
EP3659618A1 (en) 2003-02-04 2020-06-03 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
WO2005072295A2 (en) 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
SI2604285T1 (sl) 2003-05-01 2014-12-31 Cornell Research Foundation, Inc. Postopek in nosilni kompleksi za dovajanje molekul celicam
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
KR101426070B1 (ko) * 2005-09-16 2014-08-01 코넬 리서치 화운데이션,인크. Ｃｄ36 발현을 감소시키는 방법
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
ES2458870T3 (es) * 2008-02-07 2014-05-07 Cornell University Procedimientos para prevenir o tratar la resistencia a la insulina

Also Published As

Publication number Publication date
EP3272353A1 (en) 2018-01-24
JP5453320B2 (ja) 2014-03-26
EP2252312B1 (en) 2014-04-09
EP3622963A1 (en) 2020-03-18
JP2018090620A (ja) 2018-06-14
JP2017052801A (ja) 2017-03-16
US20170100450A1 (en) 2017-04-13
US20090253641A1 (en) 2009-10-08
WO2009100363A2 (en) 2009-08-13
DK2252312T3 (da) 2014-06-16
CY1115305T1 (el) 2017-01-04
US20190269749A1 (en) 2019-09-05
CN101939019B (zh) 2014-07-16
JP2019167384A (ja) 2019-10-03
EP3103467A1 (en) 2016-12-14
EP2252312A4 (en) 2011-07-06
CA2713150C (en) 2016-01-05
CN101939019A (zh) 2011-01-05
PT2252312E (pt) 2014-07-17
EP2712620A1 (en) 2014-04-02
SI2252312T1 (sl) 2014-08-29
US20120149638A1 (en) 2012-06-14
US8088727B2 (en) 2012-01-03
CN104107417A (zh) 2014-10-22
WO2009100363A3 (en) 2009-12-30
JP2014065738A (ja) 2014-04-17
ES2458870T3 (es) 2014-05-07
JP2011511805A (ja) 2011-04-14
EP3441079A1 (en) 2019-02-13
US20150359839A1 (en) 2015-12-17
JP2015227353A (ja) 2015-12-17
US20180185435A1 (en) 2018-07-05
EP2252312A2 (en) 2010-11-24
US20130303447A1 (en) 2013-11-14
CN104107417B (zh) 2017-04-12
CA2713150A1 (en) 2009-08-13
EP2902036A1 (en) 2015-08-05

Similar Documents

Publication Publication Date Title
PT2252312E (pt) Métodos de prevenção ou tratamento de resistência a insulina
IL257418A (en) Methods for treating addiction
IL212348A0 (en) Treatment method
IL205554A (en) An insulin resistance treatment containing melanocortin
IL209895A (en) Compounds for the prevention and / or treatment of β-amyloidoses
GB2462811B (en) Improved autoinjector
SG11201401811WA (en) Method for preventing and/or treating insulin resistance
GB0823213D0 (en) Treatment
GB0823693D0 (en) Autoinjector
GB0802634D0 (en) Catheter
GB0802116D0 (en) Treatment
EP2371415A4 (en) CATHETER
GB2456425B (en) Catheter
GB0822011D0 (en) Treatment
GB0806814D0 (en) Improved autoinjector
PL2441462T3 (pl) Sposób leczenia cukrzycy typu I
GB0811992D0 (en) Treatment
HU0800419D0 (en) Catheter
GB0718684D0 (en) Treatment method
GB0812019D0 (en) Insulin
EP2349285A4 (en) METHOD FOR TREATING OR PREVENTING PAIN WITH THE HELP OF SPICAMYCIN DERIVATIVES
EP2254410A4 (en) PROCESS FOR INHIBITING THE REMOVAL OF MEDICINAL PRODUCTS
GB0820972D0 (en) Treatment
GB0805912D0 (en) Treatment
GB0819893D0 (en) Catheter